Notice2023-04564
Fosun Pharma USA Inc.; Withdrawal of Approval of Abbreviated New Drug Application for Pemoline Tablets, 18.75 Milligrams, 37.5 Milligrams, and 75 Milligrams
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
March 7, 2023
Issuing agencies
Health and Human Services DepartmentFood and Drug Administration
Abstract
The Food and Drug Administration (FDA or Agency) is withdrawing approval of abbreviated new drug application (ANDA) 075286 for pemoline tablets, 18.75 milligrams (mg), 37.5 mg, and 75 mg, held by Fosun Pharma USA Inc. (Fosun), 104 Carnegie Center, Princeton, NJ 08540. Fosun requested that approval of this application be withdrawn and has waived its opportunity for a hearing.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 44 (Tuesday, March 7, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 44 (Tuesday, March 7, 2023)]
[Notices]
[Pages 14171-14172]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-04564]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2023-N-0680]
Fosun Pharma USA Inc.; Withdrawal of Approval of Abbreviated New
Drug Application for Pemoline Tablets, 18.75 Milligrams, 37.5
Milligrams, and 75 Milligrams
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is
withdrawing approval of abbreviated new drug application (ANDA) 075286
for pemoline tablets, 18.75 milligrams (mg), 37.5 mg, and 75 mg, held
by Fosun Pharma USA Inc. (Fosun), 104 Carnegie Center, Princeton, NJ
08540. Fosun requested that approval of this application be withdrawn
and has waived its opportunity for a hearing.
DATES: Approval is withdrawn as of March 7, 2023.
FOR FURTHER INFORMATION CONTACT: Kimberly Lehrfeld, Office of
Regulatory Policy, Center for Drug Evaluation and Research, Food and
Drug Administration, 10903 New Hampshire
[[Page 14172]]
Ave., Bldg. 51, Rm. 6226, Silver Spring, MD 20993, 301-796-3137,
<a href="/cdn-cgi/l/email-protection#602b090d0205120c194e2c05081206050c04200604014e0808134e070f16"><span class="__cf_email__" data-cfemail="d49fbdb9b6b1a6b8adfa98b1bca6b2b1b8b094b2b0b5fabcbca7fab3bba2">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: On June 30, 1999, FDA approved ANDA 075286
for pemoline tablets, 18.75 mg, 37.5 mg, and 75 mg, for the conditions
of use in the labeling of new drug application (NDA) 016832, the
reference listed drug on which it relied. On October 24, 2005, the
Agency issued a Postmarket Drug Safety Information for Patients and
Providers communication entitled ``Information for Healthcare
Professionals: Pemoline Tablets and Chewable Tablets (Marketed as
CYLERT)'' which concluded the overall liver toxicity risk of CYLERT
(pemoline) (NDAs 016832 and 017703) and generic pemoline products
outweighed the benefits of these products (<a href="https://wayback.archive-it.org/7993/20171114124349/https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm126461.htm">https://wayback.archive-it.org/7993/20171114124349/https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm126461.htm</a>).
All holders of approved applications for pemoline products,
including Fosun, ceased marketing the products at that time. On April
22, 2019, Fosun requested that FDA withdraw approval of ANDA 075286,
pursuant to Sec. 314.150(d) (21 CFR 314.150(d)) and waived its
opportunity for a hearing.
For the reasons discussed above, and in accordance with the
applicant's request, approval of ANDA 075286 for pemoline tablets,
18.75 mg, 37.5 mg, and 75 mg, and all amendments and supplements
thereto, is withdrawn under Sec. 314.150(d). Distribution of pemoline
tablets, 18.75 mg, 37.5 mg, and 75 mg, into interstate commerce without
an approved application is illegal and subject to regulatory action
(see sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic
Act (21 U.S.C. 355(a) and 331(d))).
Dated: March 1, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-04564 Filed 3-6-23; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on March 7, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.